John H van Duzer
Overview
Explore the profile of John H van Duzer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
603
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krukowski K, Ma J, Golonzhka O, Laumet G, Gutti T, van Duzer J, et al.
Pain
. 2017 Mar;
158(6):1126-1137.
PMID: 28267067
Chemotherapy-induced peripheral neuropathy is one of the most common dose-limiting side effects of cancer treatment. Currently, there is no Food and Drug Administration-approved treatment available. Histone deacetylase 6 (HDAC6) is...
2.
Vieson M, Gojmerac A, Khan D, Dai R, van Duzer J, Mazitschek R, et al.
Histol Histopathol
. 2017 Mar;
32(12):1317-1332.
PMID: 28245046
To date, there are 18 histone deacetylase (HDAC) enzymes, divided into four classes, which alter protein function by removing acetyl groups from lysine residues. Prior studies report that non-selective HDAC...
3.
Min C, Moore N, Shearstone J, Quayle S, Huang P, van Duzer J, et al.
PLoS One
. 2017 Jan;
12(1):e0169128.
PMID: 28060870
Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic stem cell disorders characterized by defects in myeloid differentiation and increased proliferation of neoplastic hematopoietic precursor cells. Outcomes for patients...
4.
Huang P, Almeciga-Pinto I, Jarpe M, van Duzer J, Mazitschek R, Yang M, et al.
Oncotarget
. 2016 Dec;
8(2):2694-2707.
PMID: 27926524
ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242). Like the structurally related drug ACY-1215 (ricolinostat),...
5.
Shearstone J, Golonzhka O, Chonkar A, Tamang D, van Duzer J, Jones S, et al.
PLoS One
. 2016 Apr;
11(4):e0153767.
PMID: 27073918
Therapeutic intervention aimed at reactivation of fetal hemoglobin protein (HbF) is a promising approach for ameliorating sickle cell disease (SCD) and β-thalassemia. Previous studies showed genetic knockdown of histone deacetylase...
6.
Jochems J, Boulden J, Lee B, Blendy J, Jarpe M, Mazitschek R, et al.
Neuropsychopharmacology
. 2013 Aug;
39(2):389-400.
PMID: 23954848
HDAC inhibitors have been reported to produce antidepressant and pro-cognitive effects in animal models, however, poor brain bioavailability or lack of isoform selectivity of current probes has limited our understanding...
7.
Santo L, Hideshima T, Kung A, Tseng J, Tamang D, Yang M, et al.
Blood
. 2012 Jan;
119(11):2579-89.
PMID: 22262760
Histone deacetylase (HDAC) enzymatic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM). Therefore, HDAC inhibitors used alone and in combination are being actively...
8.
Szabo C, Mabley J, Moeller S, Shimanovich R, Pacher P, Virag L, et al.
Mol Med
. 2002 Dec;
8(10):571-80.
PMID: 12477967
Background: Peroxynitrite is a cytotoxic oxidant formed from nitric oxide (NO) and superoxide. Tyrosine nitration, a footprint of peroxynitrite, has been demonstrated in the pancreatic islets as well as in...